Pratik B Sandesara1, Anurag Mehta2, Wesley T O'Neal2, Heval M Kelli2, Vasanth Sathiyakumar3, Seth S Martin3, Michael J Blaha3, Roger S Blumenthal3, Laurence S Sperling4. 1. Department of Medicine, Division of Cardiology, Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA, USA. Electronic address: psandes@emory.edu. 2. Department of Medicine, Division of Cardiology, Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA, USA. 3. Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, 601 North Caroline Street, Baltimore, MD, USA. 4. Department of Medicine, Division of Cardiology, Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA, USA; Emory Heart Disease Prevention Center, Executive Park, 1605 Chantilly Drive Northeast, Atlanta, GA, USA.
Abstract
BACKGROUND AND AIMS: Individuals with low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL are considered high-risk and current guidelines recommend initiating high-intensity statin therapy in this group. We sought to examine the predictive ability of zero CAC in this high-risk group. METHODS: Multi-Ethnic Study of Atherosclerosis participants without clinical cardiovascular disease and baseline LDL-C ≥190 mg/dL were identified. Cardiovascular risk factors were compared between those with CAC = 0 and CAC >0. Multivariable Poisson regression was used to identify predictors of CAC = 0. Association of CAC = 0 with incident cardiovascular events over a median follow-up of 13.2 years was examined using multivariable-adjusted Cox regression. RESULTS: 246 individuals (mean age = 63 ± 9.4 years; 42% male; 31% white; 37% CAC = 0) with LDL-C ≥190 mg/dL were identified (mean LDL-C = 215 ± 27 mg/dL). Age <65 years (RR = 2.17, 95%CI = 1.49-3.23), female sex (RR = 2.10, 95%CI = 1.42-3.10), and no diabetes (RR = 2.22, 95%CI = 1.18-4.17) were associated with CAC = 0. Individuals with CAC = 0 had a lower risk for future cardiovascular events (incidence rate per 1000 person-years = 4.7; 10-year risk = 3.7%; risk/year = 0.4%) than those with CAC >0 (incidence rate per 1000 person-years = 26.4; 10-year risk = 20%; risk/year = 2.0%), adjusted HR 0.25 (95%CI = 0.10-0.66). CONCLUSIONS: Among persons with LDL-C ≥190 mg/dL, younger age, female sex, and the absence of diabetes were associated with CAC = 0. CAC = 0 was associated with a low risk of cardiovascular events, suggesting the utility of CAC assessment for stratifying risk in this high-risk group.
BACKGROUND AND AIMS: Individuals with low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL are considered high-risk and current guidelines recommend initiating high-intensity statin therapy in this group. We sought to examine the predictive ability of zero CAC in this high-risk group. METHODS: Multi-Ethnic Study of Atherosclerosisparticipants without clinical cardiovascular disease and baseline LDL-C ≥190 mg/dL were identified. Cardiovascular risk factors were compared between those with CAC = 0 and CAC >0. Multivariable Poisson regression was used to identify predictors of CAC = 0. Association of CAC = 0 with incident cardiovascular events over a median follow-up of 13.2 years was examined using multivariable-adjusted Cox regression. RESULTS: 246 individuals (mean age = 63 ± 9.4 years; 42% male; 31% white; 37% CAC = 0) with LDL-C ≥190 mg/dL were identified (mean LDL-C = 215 ± 27 mg/dL). Age <65 years (RR = 2.17, 95%CI = 1.49-3.23), female sex (RR = 2.10, 95%CI = 1.42-3.10), and no diabetes (RR = 2.22, 95%CI = 1.18-4.17) were associated with CAC = 0. Individuals with CAC = 0 had a lower risk for future cardiovascular events (incidence rate per 1000 person-years = 4.7; 10-year risk = 3.7%; risk/year = 0.4%) than those with CAC >0 (incidence rate per 1000 person-years = 26.4; 10-year risk = 20%; risk/year = 2.0%), adjusted HR 0.25 (95%CI = 0.10-0.66). CONCLUSIONS: Among persons with LDL-C ≥190 mg/dL, younger age, female sex, and the absence of diabetes were associated with CAC = 0. CAC = 0 was associated with a low risk of cardiovascular events, suggesting the utility of CAC assessment for stratifying risk in this high-risk group.
Authors: Francesco Castagna; Jeremy Miles; Javier Arce; Ephraim Leiderman; Patrick Neshiwat; Paul Ippolito; Patricia Friedmann; Aldo Schenone; Lili Zhang; Carlos J Rodriguez; Michael J Blaha; Jeffrey M Levsky; Mario J Garcia; Leandro Slipczuk Journal: Circ Cardiovasc Imaging Date: 2022-06-21 Impact factor: 8.589
Authors: Alexander C Razavi; Tanika N Kelly; Matthew J Budoff; Lydia A Bazzano; Jiang He; Camilo Fernandez; Joao Lima; Khurram Nasir; Roger S Blumenthal; Michael J Blaha; Seamus P Whelton Journal: Atherosclerosis Date: 2021-03-26 Impact factor: 5.162
Authors: Anurag Mehta; Joseph Rigdon; Matthew C Tattersall; Charles A German; Thomas A Barringer; Parag H Joshi; Laurence S Sperling; Matthew J Budoff; Alain Bertoni; Erin D Michos; Michael J Blaha; James H Stein; Michael D Shapiro Journal: Circ Cardiovasc Imaging Date: 2021-04-08 Impact factor: 8.589
Authors: Martin Bødtker Mortensen; Miguel Caínzos-Achirica; Flemming Hald Steffensen; Hans Erik Bøtker; Jesper Møller Jensen; Niels Peter Rønnow Sand; Michael Maeng; Jens Meldgaard Bruun; Michael J Blaha; Henrik Toft Sørensen; Manan Pareek; Khurram Nasir; Bjarne L Nørgaard Journal: JAMA Netw Open Date: 2022-02-01